Latest news
Sarepta Therapeutics (SRPT) Brings In Michael Severino As Chief Executive Officer - simplywall.stsimplywall.st · Sat, 08 Aug 2026 10:47:29 GMTState Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G - Stock TitanStock Titan · Fri, 07 Aug 2026 14:55:22 GMTTraders Purchase Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeatMarketBeat · Fri, 07 Aug 2026 14:23:37 GMTSAREPTA THERAPEUTICS, INC. : OPPENHEIMER CUTS TARGET PRICE TO $35 FROM $37 - BitgetBitget · Fri, 07 Aug 2026 02:54:52 GMTSarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop - simplywall.stsimplywall.st · Fri, 07 Aug 2026 00:05:04 GMTSarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says - MoomooMoomoo · Thu, 06 Aug 2026 19:42:13 GMTSarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 18:05:00 GMTSarepta’s new CEO Michael Severino faces critical milestones to prove growth - Fierce PharmaFierce Pharma · Thu, 06 Aug 2026 15:15:32 GMT